In the absence of a submission from the holder of the marketing authorisation, albiglutide (Eperzan®) cannot be endorsed for use within NHS Wales for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance; or add-on combination therapy in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.